http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Novel Coronavirus Pneumonia Outbreak in 2019: Computed Tomographic Findings in Two Cases
Xiaoqi Lin,Zhenyu Gong,Zuke Xiao,Jingliang Xiong,Bing Fan,Jiaqi Liu 대한영상의학회 2020 Korean Journal of Radiology Vol.21 No.3
Since the 2019 novel coronavirus (2019-nCoV or officially named by the World Health Organization as COVID-19) outbreak in Wuhan, Hubei Province, China in 2019, there have been a few reports of its imaging findings. Here, we report two confirmed cases of 2019-nCoV pneumonia with chest computed tomography findings of multiple regions of patchy consolidation and ground-glass opacities in both lungs. These findings were characteristically located along the bronchial bundle or subpleural lungs.
Yan Liu,Fuli Wang,Yulu Xiong,Zhenyu Liu,Ruicheng Ma,Fei Chu 제어·로봇·시스템학회 2024 International Journal of Control, Automation, and Vol.22 No.3
To improve the accuracy of feature representation and abnormal condition identification, a new abnormal condition identification method, named integrating multiple binary neural networks based on condition-relevantinformation (CRI-MBNN), is presented for the electro-fused magnesia smelting process in this study. Firstly, thefeatures related to each specific abnormal condition, which is named condition-relevant information (CRI), are analyzed and extracted from the multi-source heterogeneous information with the help of limited and consensus domainknowledge. Then, the CRI is fused at the feature-level to provide a comprehensive representation of each abnormalcondition. Furthermore, for each abnormal condition, a binary neural network (BNN) is established based on thefused feature. They are further integrated according to the frequency of each condition in the actual productionprocess to form the final abnormal condition identification network, i.e., CRI-MBNN. Finally, the effectiveness andfeasibility of the proposed CRI-MBNN are verified by the electro-fused magnesia smelting process.
Menghui Liu,Shaozhao Zhang,Xiaohong Chen,Yue Guo,Xiangbin Zhong,Zhenyu Xiong,Yifen Lin,Huimin Zhou,Yiquan Huang,Zhengzhipeng Zhang,Lichun Wang,Xiaodong Zhuang,Xinxue Liao 대한당뇨병학회 2021 Diabetes and Metabolism Journal Vol.45 No.5
Background: Currently available guidelines contain conflicting recommendations on the management of blood pressure (BP) in patients with diabetes mellitus (DM). Therefore, it is necessary to appraise the guidelines and summarize the agreements and differences among recommendations.Methods: Four databases and the websites of guideline organizations were searched for guidelines regarding BP targets and thresholds for pharmacologic therapy in DM patients, and the included guidelines were appraised with the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument.Results: In 6,498 records identified, 20 guidelines met our inclusion criteria with 64.0% AGREE II scores (interquartile range, 48.5% to 72.0%). The scores of the European and American guidelines were superior to those of the Asian guidelines (both adjusted P<0.001). Most of the guidelines advocated systolic BP targets <130 mm Hg (12 guidelines, 60%) and diastolic BP targets <80 mm Hg (14 guidelines, 70%) in DM patients. Approximately half of the guidelines supported systolic BP thresholds >140 mm Hg (10 guidelines, 50%) and diastolic BP thresholds >90 mm Hg (nine guidelines, 45%). The tiny minority of the guidelines provided the relevant recommendations regarding the lower limit of official BP targets and the ambulatory BP monitoring (ABPM)/home BP monitoring (HBPM) targets and thresholds in DM patients.Conclusion: The lower official BP targets (<130/80 mm Hg) in patients with DM are advocated by most of the guidelines, but they contain conflicting recommendations on the official BP thresholds. Moreover, the gaps regarding the lower limit of official BP targets and the ABPM/HBPM targets and thresholds need to be considered by future study.